| Identification | Back Directory | [Name]
Parecoxib | [CAS]
198470-84-7 | [Synonyms]
Valus-P
Vorth-P
SC 69124
Parocoxib
Parecoxib (free)
Parecoxib USP/EP/BP
parecoxib free base
Parecoxib impurities
Valdecoxib Impurity J
Parecoxib SodiuM IMpurity W
Parecoxib Sodium Impurity 81
Parecoxib SodiuM iMpurity PR-12-I
Parecoxib (This product is unavailable in the U.S.)
N-[4-(5-methyl-3-phenyl-oxazol-4-yl)phenyl]sulfonylpropanamide
N-(4-(5-Methyl-3-phenylisoxazol-4-yl)phenylsulfonyl)propionaMide
N-[[4-(5-Methyl-3-phenyl-4-isoxazolyl)phenyl]sulfonyl]propanamide
Propanamide, N-[[4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl]sulfonyl]-
N-((4-(5-Methyl-3-phenyl-2,3-dihydrooxazol-4-yl)phenyl)sulfonyl)propionaMide | [EINECS(EC#)]
803-261-6 | [Molecular Formula]
C19H18N2O4S | [MDL Number]
MFCD08141856 | [MOL File]
198470-84-7.mol | [Molecular Weight]
370.42 |
| Chemical Properties | Back Directory | [Melting point ]
148.9-151° | [density ]
1.264 | [storage temp. ]
Sealed in dry,2-8°C | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
neat | [pka]
5.08±0.10(Predicted) | [color ]
White to off-white | [BRN ]
8640266 | [InChI]
InChI=1S/C19H18N2O4S/c1-3-17(22)21-26(23,24)16-11-9-14(10-12-16)18-13(2)25-20-19(18)15-7-5-4-6-8-15/h4-12H,3H2,1-2H3,(H,21,22) | [InChIKey]
TZRHLKRLEZJVIJ-UHFFFAOYSA-N | [SMILES]
C(NS(C1=CC=C(C2=C(C)ON=C2C2=CC=CC=C2)C=C1)(=O)=O)(=O)CC |
| Hazard Information | Back Directory | [Uses]
Anti-inflammatory; analgesic (cyclooxygenase COX-2 inhibitor). | [Definition]
ChEBI: An N-acylsulfonamide resulting from the formal condensation of valdecoxib with propionic acid. It is a prodrug for valdecoxib. | [Synthesis]
General procedure for the synthesis of N-((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)propionamide from propionic anhydride and 4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonamide: 3.1 grams (10 mmol) of 4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonamide was mixed with 3.5 grams (35 mmol) of triethylamine and 2.6 g (20 mmol) propionic anhydride in 20 mL of chloromethane. After completion of the reaction, the reaction mixture was poured into water and extracted with dichloromethane. The extract was concentrated, dissolved in ethanol, crystallized 5 to 10 times, filtered and dried to give 3.4 g of N-((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)propionamide in 92.5% yield and 99.77% purity. | [in vivo]
Parecoxib (intraperitoneal injection; 2.5, 5.0 or 10?mg/kg; once a day; 21?days) does not affect locomotor activity in the elevated plus-maze test, and Parecoxib at 5 and 10?mg/kg shows higher levels of percentage of time spent in the open arms[3]. | Animal Model: | Naive adult male ICR mice, 15?weeks old and weighing 25-35?g[3] | | Dosage: | 2.5, 5.0 or 10?mg/kg | | Administration: | Intraperitoneal injection; 2.5, 5.0 or 10?mg/kg; once a day; 21?days | | Result: | Exerted an anxiolytic-like effect in the elevated plus-maze test |
| [IC 50]
COX-2 | [References]
[1] Patent: CN105859647, 2016, A. Location in patent: Paragraph 0048; 0049; 0050
[2] Patent: CN106008387, 2016, A. Location in patent: Paragraph 0020; 0048; 0049; 0050
[3] Patent: CN106008386, 2016, A. Location in patent: Paragraph 0021; 0056; 0057; 0058
[4] Journal of Medicinal Chemistry, 2000, vol. 43, # 9, p. 1661 - 1663
[5] Patent: CN106674142, 2017, A. Location in patent: Paragraph 0038-0048 |
|
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Telephone: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15748/0_EN.htm |
|